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 Abstract 
Background 
Deep brain stimulation in the ventral tegmental area (VTA-DBS) has provided remarkable 
therapeutic benefits in decreasing headache frequency and severity in patients with medically 
refractory chronic cluster headache (CH). However, to date the effects of VTA-DBS on cognition, 
mood and quality of life have not been examined in detail.  
Methods 
The aim of the present study was to do so in a case series of 18 consecutive patients with CH who 
underwent implantation of DBS electrodes in the VTA. The patients were evaluated preoperatively 
and after a mean of 14 months of VTA-DBS on tests of global cognition (Mini Mental State 
Examination), intelligence (Wechsler Abbreviated Scale of Intelligence), verbal memory 
(California Verbal Learning Test-II), executive function (D-KEFS Stroop, verbal fluency, Trail-
making), and attention (Paced Serial Addition Test). Depression (Beck Depression Inventory (BDI), 
Hospital Anxiety Depression Scale (HADS)-Depression), anxiety (HADS-A), apathy (Starkstein 
Apathy Scale, SAS), hopelessness (Beck Hopelessness Scale, BHS), were also assessed. Subjective 
pain experience and behaviour (McGill Pain Questionnaire, Pain Behaviour Checklist) and quality 
of life (SF-36) were also evaluated at the same time points.  
Results 
VTA-DBS resulted in significant improvement of headache frequency (from mean of 5 to 2 
episodes, p < .001) and severity (from mean of  10 to 7,  p < .001) which was associated with 
significant reduction of anxiety (from mean of 11.94 to 8.00,  p < .001) and help-seeking 
behaviours (from mean of 4.00 to 2.61, p < .001). VTA-DBS did not produce any significant 
change on any tests of cognitive function and any other outcome measures (BDI, HAD-D, SAS, 
BHS, McGill Pain Questionnaire, SF36). 
Conclusion 
We confirm the efficacy of VTA-DBS in the treatment of medically refractory chronic CH. The 
reduction of  headache frequency and severity was associated with a significant reduction of 
anxiety. Furthermore, the result suggests that VTA-DBS for chronic CH improves pain-related 
help-seeking behaviours  and does not produce any change in cognition. 
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Introduction 
Cluster headache (CH) is a rare trigeminal autonomic cephalalgia (TAC) characterized by attacks of 
severe, cranial pain associated with ipsilateral autonomic symptoms such as conjunctival injection, 
lacrimation, nasal congestion, ptosis or eyelid oedema 1. CH is one of the most excruciating and 
disabling conditions and it has a severe impact on the patient's quality of life. Patients with CH 
show greater anxiety, depression and worse quality of life compared with healthy populations 2. The 
exact pathophysiology in cluster headache (CH) is matter of debate 3–10. The seasonality and 
periodicity of CH attacks are indicative of a possible hypothalamic role 7,11. This has been sustained 
by neuro-endocrinological studies 12,13 and neuroimaging studies 14,15. Early imaging studies pointed 
to increased activity and neuronal density in what was thought to be ‘the posterior hypothalamic 
region’ 16. Further studies have shown this region to lie not in the hypothalamus but in the ventral 
tegmental area (VTA) 17–19. In the course of an attack, pathological activation of the trigemino-
parasympathetic brainstem reflex is considered to cause trigeminal nerve and craniofacial 
parasympathetic activation resulting in distinctive ipsilateral cranial pain and autonomic features 
7,20. The trigemino-hypothalamic tract, which connects the posterior hypothalamic region to the 
trigeminal nucleus in the brainstem has been proposed as an important pathway in this process 21. 
Standard medical treatments of CH include acute therapy aimed at aborting individual attacks, and 
preventative medications, which reduce the frequency of attacks. These treatments are effective for 
a proportion of the patients 22. On the other hand, in a small but significant number of highly 
disabled individuals, standard medical therapy is not sufficiently effective and CH attacks are 
intractable. For these patients, deep brain stimulation (DBS) is considered as a therapeutic option. 
DBS is a surgical treatment in which electric pulses are continuously applied via stereotactically 
implanted electrodes. The first DBS procedure for CH in 2001 23 targeted the so called “postero-
medial hypothalamus” with positive results. Subsequent investigators 18,19,21 have highlighted that 
the region being targeted is more accurately termed the VTA  and have also reported beneficial 
effects of DBS of the VTA with significant reduction in the severity and the frequency of CH 
attacks 17. The aim of the present study was to investigate the effect of VTA-DBS for CH on 
cognition, mood, pain experience and behaviour, and quality of life in most of the patients who 
were also included in the clinical report of Akram et al (2016). 
Methods 
Study population 
Eighteen consecutive patients (3 female) with chronic CH (CCH), referred for VTA-DBS at the 
National Hospital for Neurology and Neurosurgery were enrolled. The patients met the 
International Classification of Headache Disorders–II diagnostic criteria for CCH 1 and had 
experienced highly disabling, medically refractory symptoms for at least 24 months. CCH was 
considered medical refractory if patients failed to respond to at least 5 of the following 7 drugs: 
verapamil, lithium, methysergide, topiramate, melatonin, gabapentin and valproate. Failure was 
defined as one of the following: unsatisfactory response, side effects intolerance or contraindication 
to the use. Moreover, all patients were considered for occipital nerve stimulation (ONS) prior to 
DBS and had either been refused funding or did not have a good response. This study was approved 
by the Local Ethics Committee. All participants gave written informed consent. Demographic and 
clinical details of the patients are presented in Table 1. 
 
Procedure 
All enrolled participants underwent clinical examination and neuropsychological assessment prior 
to surgery. Clinical and neuropsychological assessments were repeated 14 ± 4.5 months 
postoperatively. The surgical procedure has been described previously 24 and involved DBS lead 
(model 3389, Medtronic Inc.) implantation in the ipsilateral VTA or bilaterally (if symptoms were 
side alternating) under local or general anesthesia. The most deep contact location of the 
quadripolar lead was determined on a 1.5T T2 axial stereotactic MRI at a level directly above the 
mammillary bodies, anteromedial to the hypointense red nucleus and posterolateral to the 
hypointense mammillothalamic tract 24. In the weeks following surgery, open label programming 
was conducted to define optimal stimulation parameters. All devices were programmed with a 
frequency of 185 Hz and pulse width of 60 µs, gradually increasing the intensity up to 4.0 volts (V) 
on weekly intervals according to occurrence of side effects (diplopia, vertigo, oscillopsia, and 
ophthalmoplegia). Stimulation parameters are provided in Table 1. 
 
Assessment of headache frequency,  severity and load 
Headache severity was evaluated on a verbal rating scale (VRS) for pain (0 no pain and 10 the 
worst pain imaginable).  Headache frequency was described as the number of CH episodes per day. 
Headache load (HAL) is a composite score to simultaneously measure frequency, severity and 
duration of cluster headache episodes. It was calculated  as ∑  (severity [verbal rating scale] x 
duration [in hours]) of all headache attacks experienced over a 2-week period 17. These measures 
were assessed using headache diaries and were used as the clinical outcome measure. 
 
Neuropsychological Assessment 
Participants were evaluated within one month prior to the DBS procedure  and one year or more 
post-operatively (mean 14 months ± 4.5). The neuropsychological battery of tests was selected to be 
a comprehensive and assess various cognitive domains and involved assessment of global 
cognition, estimates of premorbid and current IQ, verbal and non-verbal memory, executive 
function, attention and language (for details please see ) 2.  
Global Cognition and Intelligence 
The Mini Mental State Examination (MMSE) 25  was used as a measure of global cognitive 
functioning. The National Adult Reading Test (NART) 26  was used to obtain an estimate of 
premorbid intelligence quotient (IQ), and the Wechsler Abbreviated Scale of Intelligence (WASI) 27 
was administered to obtain an estimate of current Full Scale IQ. The NART assesses reading and 
vocabulary skills. The participants are asked to read aloud 50 irregular English words. The total 
error score is used to obtain an estimate of premorbid IQ. The WASI is an abbreviated scale to 
provide a measure of current intelligence quotient (IQ). It includes 4 subscales: vocabulary, 
similarities, block design, matrix reasoning. The vocabulary scale is indicative of verbal knowledge 
and verbal concept formation. Matrix Reasoning measures non-verbal skills of fluid and abstract 
reasoning. In the Short form of the WASI, the Vocabulary and Matrix Reasoning scores are used to 
obtain an estimation of the current Full Scale IQ. 
Verbal and Non-Verbal Memory 
The California Verbal Learning Test (CLVT-II) 28 is a test of episodic verbal memory for words 
that provides data on immediate memory span, verbal learning, short/long term free and cued recall 
and delayed recognition of of 16 words, which belong to four semantic categories.  
The Recognition Memory for Faces-short form (SRMF) 29 was used to assess non-verbal 
recognition memory for faces. SRMF consists of two phases.  In the first phase, 25 photographs of 
male faces are shown at the speed of 1 every 3 seconds. The participant is asked to indicate if they 
consider the face to be pleasant or not pleasant. In the second  phase, 25 pairs of faces are shown 
and the participant is asked to identify which of the two faces had been previously presented. The 
score is the total number of correctly recognized faces.  
Executive Functions and Inhibition 
The Delis–Kaplan Executive Function System (D-KEFS) 30 is a set of tests sensitive to verbal and 
nonverbal executive functions. In our study, the following subtests were used to assess executive 
function: the Trail Making Test (TMT), the phonemic, semantic and alternating categories Verbal 
fluency (VF) and the Colour-Word Interference Test (Stroop). In the D-KEFS verbal fluency the 
participant has 60 seconds to orally produce as many words as possible. There are three conditions: 
in the first condition (letter fluency) the participants are presented with a letter ( F, A and S) and 
asked to say as many words as possible starting with that letter. In the second phase (category 
fluency) the participants are asked to say as many words as possible in the category of animals and 
boy’s  names. In the third phase (switching) the participant is asked to say as many words as 
possible alternating between a fruit and furniture category. The score for each condition is the total 
number of correct items produced. Based on the original test designed by Stroop (1935), the Delis-
Kaplan Colour-Word Interference test consists of four subtests. The “colour naming” (naming 
colour of ink of coloured rectangles) and “word reading” (reading colour words printed in black 
ink) subtests serve as control conditions. The main ‘Stroop’ test is the “inhibition” subtest which 
presents the names of colour words such as red, green and blue on the page printed in an 
incongruent colour of ink. For example, the word red is printed in blue ink. The patient has to name 
the colour of the ink as fast as they can.  This requires inhibition of the more habitual and prepotent 
response of reading the word. Executive functions employed in this subtest are response inhibition, 
cognitive control and flexibility 30.  The final inhibition/switching condition also involves colour 
words printed in incongruent ink and requires switching between naming the colour of ink they are 
printed in and reading the word when the word is surrounded by a box.  This condition has the 
additional requirement of switching between two task sets. The Trail Making Test includes 5 
conditions 30:visual scanning, number sequencing, letter sequencing, number and letter switching 
and motor speed. In the visual scanning subtest the participants were shown letters and numbers and 
asked to strike off all “3s” presented in a group of letters and other numbers. In the number 
sequencing subtest the participants were asked to join all the numbers in progressive order ignoring 
the letters. In the letter sequencing subtest, the participants were asked to connect all the letters in 
alphabetical order and to ignore the numbers. In the  number-letter switching subtest, the 
participants were asked to join numbers and letters in two alternating sequences of a number and 
then a letter (eg 1-A-2-B-3-C…).  The motor speed test required the participants to be as quick as 
possible to trace dashed lines connecting circles.  The executive functions believed to be important 
for the successful completion of this test are: behavioural regulation, cognitive flexibility and 
inhibition of perseverative responding. 
Attention 
The Paced Auditory Serial Addition Test (PASAT) 31 involves presentation via a tape-recorder of a 
series of 31 numbers between 1 and 9. The patient is required to add each number read out to the 
immediately preceding one and say out their sum.  Performance engages working memory and 
sustained attention.  The percent correct is calculated. 
Depression and anxiety 
The Beck Depression Inventory (BDI-II) 32 is a self-report inventory assessing the severity of 
depression with regard to the cognitive,affective, somatic, or behavioural symptoms.  Scores range 
from 0 to 63, with higher scores denoting higher depression. The Hospital Anxiety and Depression 
Rating Scale (HADS) 33 is a self-report measure assessing depression and anxiety. The sum of items 
in each subscale represents a total score indicating global anxiety (HADS-A) or depression (HADS-
D).  On both Depression and Anxiety subscales scores range from 0 to 21, with higher scores 
indicating more severe depression or anxiety and scores above 11 considered ‘caseness’.   
Hopelessness 
The Beck Hopelessness Scale (BHS) 34 is a self-report measure of three major aspects of 
hopelessness: feelings about the future, loss of motivation, and expectations. The sum of items 
ranges from 0 to 20, and higher scores are indicative of higher hopelessness.  
Apathy 
The Starkstein Apathy Scale (SAS) was used to assess reduction of interest, motivation, affective  
responsivity, and engagement in goal-directed behaviours. The SAS consists of 14 items that are 
answered on a four point Likert scale (scores: ‘not at all’, ‘slightly’, ‘some’, ‘a lot’). The total 
scores range from 0-42 and greater scores indicate more severe apathy 35. 
Pain experience and behaviour 
The McGill Pain Questionnaire (MPQ) 36 contains 78 pain descriptors assigned to three categories 
of pain qualities: sensory, affective, and evaluative.  There is also a miscellaneous category of pain-
related words. The Pain Behaviour Checklist (PBC) 37 is a self-report assessment to quantify three 
classes of pain behaviours: help seeking, avoidance, and complaint. 
Quality of Life 
The Short Form-36 (SF-36) is a 36 item questionnaire which measures Quality of Life (QoL) across 
eight domains (physical and social functioning, physical and emotional role limitations, mental 
health, energy, pain, and general health perceptions). Eight different subscores, and a physical and 
mental summary score can be derived. The maximum score ranges from 0 (lowest or worst possible 
level of functioning) to 100 (indicates the best possible health state).  
 
Statistical analysis 
All data were analysed using the computing environment R 38. The data for all tests were first 
assessed for presence of outliers, the parametric assumptions of normality (Shapiro-Wilk Test), and 
homogeneity of variance (Bartlett’s Test). When the assumptions for parametric analysis were met, 
paired samples t-tests were used to compare cognitive, mood, pain and quality of life measurements 
before and after VTA-DBS. When the assumptions were violated, nonparametric Wilcoxon signed 
ranks test was used and the median was given instead of the mean. To protect against Type I Error, 
for each outcome measure domain (Cognitive, Mood, Pain and Quality of Life) a Bonferroni 
correction was completed and applied. Thus the corrected p value was used for determination of 
significance of the results in each domain.  The corrected p-value for the measures of Cognitive 
function is p=.001 (that is αaltered = .05/30 = .001).   For the measures of Mood the corrected  p = 
.01; for Pain-related Behaviours it is p = .006;  for the Quality of life measure it is p = .006. 
Furthermore, to determine if any of the post-operative changes were statistically reliable, we 
calculated the reliable change index (RCI). RCI verifies if variation in a score is statistically strong 
and reliable 39. The formula for calculating it is:  
 
Mean of post operation score minus mean of pre operation score divided by the standard error of the 
difference. The formula for calculating the standard error of difference is: 
 The RCI cut off is 1.96, RCI < - 1.96 are considered a reliable decline, RCI > + 1.96 are considered 
a reliable improvement, RCI between – 1.96 and + 1.96 are not considered as reflecting reliable 
change. We also calculated the confidence intervals of reliable changes for specific measures. The 
formula for calculating this is: 
 
Based on this score the results are then regrouped into three classes representing the percentages of 
the participants with reliable decline, no change and reliable improvement. 
 
Results 
 Headache frequency, severity and load before and after surgery 
Headache frequency measured as the number of daily attacks was significantly reduced from 5 to 2 
after VTA-DBS (p < .001). Indicating that there was a 52% overall improvement in headache 
frequency. Fifty five percent of patients had a reduction of  ≥ 40% on the number of  daily attacks 
after VTA-DBS. Headache severity assessed on the verbal rating scale (VRS) was significantly 
reduced from 10 to 7 after VTA-DBS (p < .001), indicating that there was a 30% overall 
improvement in headache severity. Forty percent of patients had a reduction of  ≥ 30% on the VRS 
after VTA-DBS. Headache load (HAL) was significantly reduced after (Median = 177.00) 
compared to before VTA-DBS (Median= 757.00), p < .005, r = -.72. Thirteen patients (72%)  had a 
reduction of  ≥ 30% on the HAL score after VTA-DBS. Their measures of cognitive function, and 
mood, pain, disability, quality of life before and after surgery are shown respectively in Tables 2 
and 3. 
Cognitive Function before and after VTA-DBS  (see Table 2) 
Measures of global cognition and intelligence 
Similar to the pre-operative MMSE score, the group median MMSE score at follow-up was also 
within the normal range. With the corrected p value of .001, the differences between pre and post 
DBS surgery in the MMSE scores were not significant. There were no significant differences 
between pre- and post-DBS measures of the WASI estimate of current Full Scale IQ. There were no 
significant differences between pre- and postoperative measures of estimated premorbid IQ 
(NART), and between current and estimated premorbid IQ either before (p = .57) or after (p = .38) 
surgery. 
Executive Functions and inhibition 
The pre- and post-DBS scores on the measures of executive function on the Trail-making, the 
Stroop and the verbal fluency tasks are presented in Table 2. The scaled score for the total correct 
category switches on the alternating category VF test was lower after (M = 8.33, SD = 1.97) than 
before (M = 10.17, SD = 4.09) surgery, but this change was not significant at the corrected p value 
of p<.001. The reliable change index (RCI= - 0.59) also indicated that this was not a reliable 
change. There were no other significant differences between pre- and post-measures on the D-KEFS 
subtests of the Trail-Making Test, verbal fluency or Stroop Colour-Word interference. 
 
Memory 
As evident from Table 2, there were no significant differences between pre and post VTA-DBS 
measures derived from the CVLT-II  or  on the short Recognition Memory for Faces (all p>.001). 
Pain experience and behaviour before and after VTA-DBS (Table 3) 
After Bonferroni correction there were no significant differences on the Pain-Behaviour Checklist 
(PBC) total scores after (M =21.78, SD = 15.09) compared to before (M = 27.60, SD = 11.02), t(14) 
= 2.17, p =.047, r = .50  surgery. However, the PBC Help Seeking behaviours were significantly 
reduced after (M =2.61, SD = 1.50) compared to before (M = 4.00, SD = 1.00), t(14) = 4.36, p < 
.001, r = .76  surgery, suggesting less engagement in  help-seeking behaviours for their CH pain 
from patients after surgery (Figure 1 A). The reliable change index (RCI= -4.43) indicates that this 
change is reliable. At post-surgical follow-up, a larger proportion of the participants showed 
improvement (80 %) than no change (13 %) or decline (6 %) in help-seeking behaviours. The 
avoidance and complaints subscales of the PBC were not significantly altered by DBS. There were 
no statistically significant differences between pre- (M = 46.06, SD = 19.35) and post-surgery (M = 
50.28, SD = 15.97), t(12) = 0.10, p = 0.92 scores on the McGill Pain Questionnaire or any of the  
sensory, evaluative, affective or miscellaneous subscores (see Table 3).  
Measures of mood and quality of life before and after VTA-DBS (Table 3) 
After Bonferroni correction, on the HADS-A scale, self-reported anxiety levels were significantly 
reduced after (M = 8.00, SD = 4.51) compared to before VTA-DBS (M = 11.94, SD = 4.36), t(17) = 
5.43, p < .001, r = .79. (Figure 1 B). The reliable change index (RCI = -2.86) indicated a reliable  
reduction of anxiety. At follow up, 61 % of patients had a reliable reduction of anxiety, 39% had no 
change and no patient had an increase of anxiety. While the means suggest some improvement in  
depression after surgery, there were no statistically significant differences between pre (M= 23.11, 
SD= 11.88) and post (M=20.55, SD=12.16 ), t(17) = 1.50, p= .15  surgery measures of the Beck 
Depression Inventory.  Similarly, there were no statistically significant differences between pre  
(M=11.61,SD=5.09) and post  (M=10.67,SD=5.82) surgery scores on the HADS-D, t(17) = 1.22, p 
= .23.  Scores on the Hopelessness Scale and the Starkstein Apathy Scale were not altered by 
surgery (see Table 3 for the pre and post-operative means).  On the SF36 measure of quality of life, 
the score on the Social Role Functioning subscale was  higher after (Median=43.75) compared to 
before (Median = 25.00), indicating better social functioning of patients after VTA-DBS, however 
after Bonferroni correction this was not significant. Similarly, on the SF36,  the score on the 
emotional wellbeing subscale was higher after (M =55.44) compared to before (M = 47.06), 
surgery, indicating greater emotional wellbeing of patients after  VTA-DBS, however after 
Bonferroni correction the improvement was not significant. Nevertheless, at follow up 46 % of the 
patients had better social functioning. 
Correlational Analysis 
Pearson correlational analyses were performed, to explore the relationship between the change 
scores in Headache Load (before and after VTA-DBS) and change scores in mood, pain experience 
and behaviour, and quality of life  (listed in Table 3) and cognitive measures (listed in Table 2). 
Variations  in anxiety levels correlated positively and significantly with changes in Headache Load 
(r = 0.57, p < .01).  None of the other correlations were of a notable magnitude or significant. 
 
 
Discussion 
A previous clinical study provided evidence for the positive impact of VTA-DBS on CH severity 
and frequency 24. In particular Akram and colleagues demonstrated a significant decrease in 
headache frequency, severity and load after surgery, with an associated relative decrease of triptan 
medication intake. However, to our knowledge, the influence of VTA-DBS on measures of 
cognition, mood, pain experience and behaviour, and quality of life has not been previously 
examined in detail, which was the aim of this study. We found that VTA-DBS produced clinical 
benefits on CH frequency, severity and  load and produced no adverse effects on cognitive function, 
but was associated with significant decrease of anxiety, and significant improvement of pain-related 
help-seeking behaviours indicating better coping with pain after surgery.  
 
Akram and colleagues defined the target area for the DBS electrode as the ventral tegmental area 
(VTA). The VTA, is the most anterior aspect of the midbrain tegmentum and encloses distinct types 
of neuronal cells. However, it is mainly distinguished by its abundant number of dopamine (DA) 
neurons.Together with the substantia nigra, the VTA is considered to be a main dopaminergic 
territory in the brain 40. Projections of dopaminergic neurons start from the VTA to reach various 
regions of the cortex through two main routes: the mesocortical and the mesolimbic dopaminergic 
pathways. The former transmits information from the VTA to prefrontal, orbitofrontal and cingulate 
cortices. The dorsolateral prefrontal cortex (DLPFC) 41,42, receives dopaminergic signals from VTA 
and it has been charachterized to be an important node for a range of cognitive funtions such as 
working memory 43,44, behavioural flexibility and inhibitory control of willed actions 45,46  aspects 
of social cognition, emotional regulation, memory retrieval 47 and implicit temporal processing 48–50. 
Thus, dopaminergic projections to the forebrain, including the frontal lobes and the dorsal and 
ventral striatum, constitute a fundamental part of the neural circuits  underlying a variety of 
cognitive and executive functions. A recent patch clamp electrophysiology study in rats 
demonstrated the functional importance of  VTA terminals to driving intrinsic inhibition in the PFC 
51. The mesolimbic path projects from the VTA to reach different limbic areas. In particular there 
are numerous connections with the nucleus accumbens (NAc). Among the functions that have been 
attributed to this mesolimbic dopaminergic circuit there is  the  regulation of the reward system 52. It 
has been shown that VTA dopamine neurons are responsive to anticipation of  time of reward, 
unpleasant or new stimuli 53–55. Recently,  a computational model of the afferents to the VTA that 
replicates many of the  experimental observations has been proposed 56. In light of the connectivity 
of the VTA with the prefrontal cortex, in the present study, we administered subtests of the Delis–
Kaplan Executive Function System (D-KEFS) 30  a set of  tests to assess verbal and nonverbal 
executive functions before and after VTA-DBS to test for any possible  effects on ‘prefrontal’ 
executive functions. The results showed that VTA-DBS surgery did not significantly alter any of 
the measures of executive function  included. 
 
Effect of VTA-DBS on cognitive function 
Cognitive function in CH has been examined in previous studies.  While some have reported 
impairments in verbal memory in CH 57, others did not find any significant differences in memory 
or executive function in CH patients relative to healthy controls 58. In a previous study by our 
group, Torkamani et al (2013) found no impairment in IQ, verbal memory or executive functions in 
patients with chronic or episodic CH relative to matched healthy controls and only deficits in 
working memory and self-reported cognitive failures were documented.  Other evidence has 
suggested that cognitive performance in CH is altered only during headache attacks 59, due to the 
fact that pain can also make demands on attentional resources 60. In this study, we examined the 
impact of VTA-DBS on global cognitive function and more specific cognitive domains of 
intelligence, executive function, memory and attention. The effective site of the DBS for CH in the 
ipsilateral hypothalamus was shown to have high probability connectivity to the frontal cortex21,61.  
In a similar vein, it is likely that stimulation through electrode contacts located in the VTA 
modulates distant neuronal dynamics through its electrical and chemical influences. However, we 
observed no significant cognitive changes in executive function after VTA-DBS (see Table 2). 
Previous research 2 showed no major deficits on tests of executive function in CH patients relative 
to healthy controls, including the Stroop and verbal fluency tests also employed here, and the results 
of the present study provide unique data that indicate that surgical implantation of electrodes and 
chronic stimulation of the VTA is generally safe from a cognitive perspective.  
 
Effect of VTA-DBS on pain experience and behaviour, mood and quality of life 
The impact of CH on mood, daily functioning and QoL has been measured in a number of previous 
studies.  These have reported that patients with CH had elevated levels of depression, suicidal 
ideation, anxiety, hopelessness, and increased disability and poorer QoL relative to healthy controls 
2,11,57,62–64. Anxiety symptoms, as measured by the HAD-A, significantly improved after DBS-VTA 
surgery. The RCI confirmed these changes showing that one year postoperatively  the majority of 
patients showed improvement (61 %)  and none of the participants showed worsening of anxiety 
after VTA-DBS. It is difficult to determine whether this beneficial effect on anxiety is generated by 
VTA stimulation directly altering the activity in the mesolimbic circuits, or indirectly because 
VTA-DBS reduced headache frequency and severity. In current experimental  paradigms, anxiety 
has been operationalized as an emotional response to potential threats. VTA is a crucial region in 
the anxiety circuit and  receives both excitatory glutamatergic and inhibitory GABAergic inputs 
from the ventral bed nucleus stria terminalis (vBNST). The current concept is that two parallel 
vBNST-to-VTA pathways mediate either anxiogenic or anxiolytic behavioural response. 
Specifically,  activation of glutamatergic vBNST inputs to the VTA increased anxiety and induced 
avoidance, whereas activation of GABAergic inputs enhanced anxiolytic effects 65. Therefore, a 
possible explanation for the reduction of anxiety following VTA-DBS might be that the stimulation 
disrupts the glutamatergic inputs from vBNST. Another possibility is  that stimulating VTA leads to 
a similar effect to the GABAergic inputs that produce anxiolytic effects.  A second explanation is 
that anxiety reduction is secondarily related to reduced headache frequency and severity. Further 
work is required to establish the mechanisms of the reduction of anxiety following VTA-DBS. 
.  
On the Pain Behaviour Checklist, the help-seeking behaviours were significantly reduced after 
VTA-DBS compared to before surgery, suggestive of better adjustment and coping with pain. The 
RCI endorsed these changes showing that more patients showed improvement (80%) than 
deterioration (13 %) or no change (6 %) on the Pain Behaviour Checklist after VTA-DBS. 
However, the changes in the severity or qualitative aspects of pain experience on the McGill Pain 
Questionnaire were not altered following VTA-DBS. Hopelessness and apathy were also not 
significantly altered by surgery. Depression, showed a trend toward reduction (pre-operative, 
M=23.11, post-operative, M=20.55) but was not significantly changed by surgery. With VTA-DBS, 
the social role functioning and emotional wellbeing components of QoL on the SF36 improved, 
albeit non-significantly after Bonferroni correction.   
A major limitation of this study is  the small sample size. However given the infrequency of the 
VTA-DBS procedure for refractory CH the current sample is satisfactory. A second limitation is 
that multiple comparisons were conducted which increases the risk of type 1 error.  To overcome 
this limitation we conducted a Bonferroni correction. Despite these limitations, the study provides 
new information about DBS-VTA safety and efficacy. In conclusion, VTA-DBS, did not produce 
any adverse cognitive effects on the measures of cognition assessed and  was associated with 
significant improvement of anxiety and help-seeking pain-related behaviours and non-significant 
improvement of the social role functioning and emotional wellbeing aspects of quality of life one 
year after surgery in our sample of CH patients.   
 
 
 
 
 
 
 
 
 
 
Article Highlights: 
 Deep brain stimulation of the ventral tegmental area (VTA-DBS) in patients with medically 
refractory chronic cluster headache (CH) did not induce any significant adverse cognitive 
effects. 
 There was significant improvement of anxiety symptoms after VTA-DBS. 
 There was significant reduction of help seeking pain-related behaviours after VTA-DBS 
suggestive of better adjustment and coping with pain after surgery. 
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Figure 1:  
Boxplots showing the distribution of values before and after VTA-DBS for (A) Pain Behaviour 
Checklist Help Seeking Behaviours, (B) Hospital Anxiety & Depression Scale, Anxiety subscale. 
Black dots represent patients’ raw scores. The solid line represents zero change. Values above the 
top dotted line represent a reliable increase in scores from baseline to follow-up after VTA-DBS. 
Values below the lower dotted line represent a reliable decrease in scores from baseline to follow-
up after VTA-DBS, values between the dotted lines represent no reliable change. 
Table 1. Demographic and clinical details and deep brain stimulation (DBS) parameters of the patients with cluster headache.  
 
 
ID Age 
(years) 
Gender  Duration 
(years) 
 electrode_positions 
(hemisphere) 
DBS 
intensity_left 
(V) 
DBS 
intensity_right 
(V) 
DBS 
frequency_left 
(Hz) 
DBS 
frequency_right 
(Hz) 
DBS pulse 
width_left 
(µS) 
DBS pulse 
width_right 
(µS) 
1 46 M 7 right - 2.1 - 185 - 60 
2 49 M 25 left 0.9 - 185 - 60 - 
3 41 F 4 bilateral 3.0 3.0 185 185 60 60 
4 58 M 14 left 3.0 - 130 - 60 - 
5 42 F 21 bilateral 2.2 2.5 185 185 60 60 
6 67 M 14 right - 1.0 - 185 - 60 
7 67 M 15 left 1,5 - 185 - 60 - 
8 33 M 17 right - 2.7 - 185 - 60 
9 49 F 11 left 1.5 - 185 - 60 - 
10 43 M 28 right - 3.0 - 185 - 60 
11 37 M 23 right - 3.0 - 185 - 60 
12 39 M 13 bilateral 3.0 1.5 185 185 60 60 
13 41 M 15 left 3.0 - 185 - 60 - 
14 53 M 22 left 3.2 - 185  60 - 
15 59 M 20 bilateral 4.0 4.0 185 185 60 60 
16 48 M 15 right - 3.5 - 185 - 60 
17 45 M 5 bilateral 3.0 3.0 185 185 60 60 
18 56 F 12 left 3.5 - 185 - 60 - 
 46.73 M=78% 
F=22% 
11.94 Right=6 
Left=7 
Bilateral=5 
      
Table 2. Means and standard deviations for the measures of cognitive function before and after VTA-DBS and reliable change indices 
(RCI) showing percent with decline, no change and improvement on the cognitive measures.  
Measure Sample Pre-operative Post-operative p= 
correct
ed 
p<.001 
Decline 
% 
No 
Change 
% 
Improve 
% 
Overall RCI 
Improvement > 1.96 
Decline < 1.96 
No change -
1.96<RCI<1.96 
Global Cognition         
Mini Mental State Examination 18 29.11 ±  1.53 28.27 ±  1.45    .03 55.5 33.3 11.1 - 1.72 
Measures of Intelligence         
WASI-full scale IQ 18 106.72  ±  14.93 103.83 ± 15.43   .07 11.1 88.9 0.0 -0.33 
National Adult Reading Test 18 108.94  ±   8.79 
 
109.19  ± 4.96   .72 
 
12.5 68.7 18.7 0.18 
California Verbal Learning Test-II         
Trial 1 18 6.17 ± 2.12 6.05 ± 1.98 .97 27.8 50.0 22.2 - 0.17 
Trial 1-5  18 48.78  ± 12.60 
 
48.06  ± 11.95 .74 
 
33.3 
 
38.9 27.8 - 0.30 
Short delay-free recall 18 9.47 ± 3.41 9.00 ± 3.97 .50 11.8 82.4 5.9 - 0.33 
Short delay-cued recall 18 10.76 ± 3.15 10.11 ± 3.30 .37 35.3 52.9 11.8 0.53 
Long delay-free recall 18 9.71 ± 3.06 9.28 ± 3.54 .41 23.5 70.6 5.9 - 0.37 
Long delay-cued recall 18 10.71 ± 3.02 10.50 ± 3.29 .85 23.5 64.7 11.8 - 0.12 
Recognition-hits 18 13.41 ± 3.24 14.94 ± 8.34 .96 29.4 47.1 23.5 1.60 
Recognition-false positives 18 1.53 ± 1.84 2.61 ± 2.61 .13 11.8 58.9 29.4 1.85 
Warrington Short Recognition Memory for Faces         
Total correct responses (max 25) 18 22.82 ± 2.30 22.83 ± 2.20 
 
.95 
 
11.8 70.6 
 
17.6 0.00 
D-KEFS  measures of executive function          
TRAIL MAKING TEST scaled scores         
Visual Scanning 18 9.11 ± 1.99 8.82 ± 3.06 .58 29.4 52.9 17.6 - 0.55 
Number sequencing 18 9.50 ± 2.04 10.35 ± 2.26 .07 11.8 47.1 41.2 1.17 
Letter sequencing 18 9.10 ± 3.39 9.53 ± 3.16 .33 5.9 58.8 35.3 0.37 
Number-letter switching 18 9.12 ± 3.28 
 
9.47 ± 3.39 .37 
 
11.8 
 
76.5 11.8 0.34 
Motor Speed 18 9.00  ± 3.46 8.65 ± 3.30 .30 29.4 58.8 11.8 - 0.89 
Letter-number switching vs letter sequencing 18 9.35  ± 2.23 9.06 ± 2.07 .53 11.8 82.4 5.9 - 0.42 
VERBAL FLUENCY scaled scores         
Letter 18 9.00 ± 4.00 8.17  ± 3.31 .09 11.1 88.9 0.00 - 0.65 
Category 18 8.94 ± 3.30 8.72  ± 2.70 .69 22.2 55.6 22.2 - 0.21 
Category Switching 18 10.39  ± 3.84 9.67 ± 1.71 .47 27.8 55.6 16.7 - 1.42 
Total Correct inhibition/switching 18 10.17  ± 4.09 8.33  ± 1.97  .04 27.8 66.7 5.6 - 0.59 
Total set loss errors 18 12.44  ± 0.98 11.61  ± 1.91 .09 38.9 44.4 16.7 - 1.10 
Total repetition errors 18 10.72  ± 2.40 11.22  ± 2.39 .43 16.7 55.6 27.8 0.66 
STROOP COLOUR-WORD INTERFERENCE 
scaled scores 
        
Colour naming 18 9.22 ± 2.88 8.66 ± 3.31 .46 27.8 55.6 16.7 - 0.61 
Word reading 18 9.17 ± 3.03 8.50 ± 2.87 .34 22.2 61.1 16.7 - 0.69 
Inhibition 18 9.33 ±  3.41 8.22 ± 3.10  .06 33.3 55.6 11.1 - 1.03 
Inhibition/switching     18     9.44 ± 3.33       8.39 ± 3.34    .16 27.8 55.6 16.7 - 1.01 
Inhibition vs  colour naming 18 10.11 ±2.53   9.55 ± 2.88 .48 22.2 61.1 16.7 - 0.69 
Attention         
Paced Auditory Serial Addition Test         
Percent correct 16 69.59 ± 23.44   64.44 ± 21.23 .08 20.0 73.3 6.7 - 0.84 
 
VTA-DBA=ventral tegmental area deep brain stimulation;  D-KEFS= Delis-Kaplan Executive Function System. 
 
  
 
 
 
Table 3. Means and standard deviations for the measures of mood, pain, disability and quality of life 
before and after VTA-DBS surgery.  
Measure N 
 
Pre-Operative Post-Operative  
corrected 
p=.01, 
p=.006 
     
Beck Depression Inventory  18 23.11 ± 11.88 20.55± 12.16 .15 
 
HADS-D 
 
18 
11.61 ± 5.09 10.67 ± 5.82 .23 
     
Beck Hopelessness scale 18 8.61  ± 5.43 8.39 ± 6.41 .62 
     
Starkstein Apathy Scale 18 20.83 ± 9.19 20.23 ± 7.02 .70 
     
HADS-A 18 11.94  ± 4.36 8.00 ± 4.51   .001* 
 
Pain 
 
 
   
PAIN BEHAVIOURAL CHECK LIST     
Pain Behaviour Checklist (PBC)_total 15 27.60 ± 11.02 21.78 ± 15.09  .04 
PBC Help Seeking Behaviour 
 
15 
 
4.00 ± 1.00 2.61 ± 1.50     .006* 
PBC Avoidance 15 17.73 ± 9.73         14.94 ± 11.39 .23 
PBC Complaint 15 5.87 ± 2.23           4.28 ± 2.86 .08 
McGill Pain Questionnaire 14    
Total 14 46.06 ± 19.35           50.28 ± 15.97           .92 
Sensory  14 22.76 ± 10.80           26.86 ± 8.04           .43 
Affective 14 8.88 ± 4.23           8.43 ± 4.07          .68 
Evaulative 14 4.35 ± 1.49           4.29 ± 1.07                   .06 
Miscellaneus 14 10.06  ± 5.28           10.71 ± 4.44          .36 
 
Quality of life 
 
 
   
SF-36 16    
SF-36 General Health 16 43.85 ± 20.77  50.94 ± 26.60 .21 
SF-36 Physical functioning 16 59.59 ± 26.95    62.50 ± 27.20  .14 
SF-36 Physical role functioning 16 36.98  ± 31.52   37.65 ± 39.17 .64 
SF-36 Emotional role functioning 16 45.98  ± 36.23   51.04 ± 39.31 .68 
SF-36 Bodily pain 16 24.56 ± 26.33   39.22 ± 34.42 .07 
SF-36 Social role functioning 16 28.68 ± 29.24  44.53 ± 31.28 .04 
SF-36 Energy/Fatigue 16 21.76 ± 26.39        28.44 ± 27.85 .15 
SF-36 Emotional Well-being 16 47.06  ± 26.29                 55.44 ± 25.84         .03 
 
HADS = Hospital Anxiety and Depression rating scale; A = anxiety; D = depression; N = sample size; PBC 
= pain behaviour checklist; SF-36 =  Short Form Health Survey questionnaire; VTA-DBS =ventral 
tegmental area deep brain stimulation. 
 
 
